Table 3.

Baseline and time-varying FGF23 levels and risk of death

Deaths, nUnadjustedModel 1Model 2Model 3Model 4
Baseline FGF23a
 Including all deaths
  5931.56 (1.38−1.78)1.72 (1.51−1.95)1.60 (1.39−1.85)1.50 (1.30−1.72)1.46 (1.27−1.69)
 ESRD-censored deaths
  3981.72 (1.54−1.93)1.80 (1.57−2.05)1.76 (1.51−2.04)1.62 (1.38−1.89)1.58 (1.34−1.85)
Time-varying FGF23b
 Including all deaths
  5931.74 (1.60−1.89)1.82 (1.67−1.97)1.81 (1.65−2.00)1.75 (1.59−1.92)1.84 (1.67−2.03)
 ESRD-censored deaths
  3981.94 (1.77−2.12)2.01 (1.82−2.21)2.06 (1.85−2.30)1.99 (1.78−2.22)2.05 (1.84−2.29)
  • All results are reported per 1-SD increase in lnFGF23 from the CRIC Study baseline visit. Model 1: stratified by center and adjusted for age, sex, race, and ethnicity. Model 2: model 1 plus eGFR, UACR, serum albumin, and hemoglobin. Model 3: model 2 plus diabetes, smoking, systolic BP, body mass index, history of coronary artery disease, history of heart failure, history of stroke, and history of peripheral vascular disease. Model 4: model 3 plus calcium, phosphate, and PTH.

  • a Adjusted for covariates at the CRIC Study baseline visit.

  • b Adjusted for time-varying covariates except sex, race, ethnicity, and UACR from the CRIC Study baseline visit.